View More Recent Stories

Nov 22, 2021 07:30AM Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
Nov 22, 2021 07:30AM Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
Nov 17, 2021 07:32AM Mirati Therapeutics (MRTX) Announces Submission of IND to FDA of MRTX1719 to Treat MTAP-Deleted Cancers
Nov 17, 2021 07:30AM Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers
Nov 9, 2021 09:00AM Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
Nov 8, 2021 04:01PM Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
Nov 1, 2021 04:30PM Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021
Oct 7, 2021 04:30PM Mirati Therapeutics (MRTX) Announces Collaboration with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer
Oct 7, 2021 04:30PM Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer
Oct 4, 2021 04:30PM Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer
Sep 24, 2021 04:15PM Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Sep 20, 2021 08:21AM Mirati (MRTX) Announces Long-term Survival Results from Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous NSCLC Who are Resistant to Checkpoint Inhibitors
Sep 20, 2021 08:20AM Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Check
Sep 20, 2021 07:55AM Mirati Therapeutics (MRTX) Appoints David Meek as CEO
Sep 20, 2021 07:55AM Mirati Therapeutics Appoints David Meek as Chief Executive Officer
Sep 20, 2021 07:31AM Mirati Therapeutics (MRTX) Announces Positive Phase 2 Results for Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Sep 20, 2021 07:30AM Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Sep 19, 2021 06:20PM Mirati Therapeutics (MRTX) Presents Positive Results From First Cohort of Phase 1/2 KRYSTAL–1 Study
Sep 19, 2021 09:47AM Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer
Sep 15, 2021 04:15PM Mirati Therapeutics to Host Virtual Investor Event on Monday, September 20, 2021
Aug 25, 2021 04:30PM Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers
Aug 5, 2021 04:15PM Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates
Jun 28, 2021 08:00AM Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition
Jun 24, 2021 04:44PM Mirati Therapeutics (MRTX) Granted FDA Breakthrough Therapy Designation For adagrasib
Jun 24, 2021 04:42PM Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation
Jun 2, 2021 04:15PM Mirati Therapeutics to Take Part in the 42nd Annual Goldman Sachs Global Healthcare Conference
Jun 1, 2021 07:36AM Mirati Therapeutics (MRTX), Zai Lab (ZLAB) Enter Into Collaboration to Develop and Commercialize Adagrasib in Greater China
Jun 1, 2021 07:30AM Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
Jun 1, 2021 07:30AM Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
Jun 1, 2021 07:30AM Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
May 6, 2021 04:15PM Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates
Apr 19, 2021 09:00AM Stand Up To Cancer Announces $4 Million Grant From Mirati Therapeutics To Support Research On KRAS Mutant Cancers
Apr 10, 2021 02:35PM Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
Mar 31, 2021 07:35AM Mirati Therapeutics (MRTX) Board Elects Shalini Sharp as New Independent Director
Mar 31, 2021 07:30AM Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director
Apr 13, 2016 04:13PM Qiagen (QGEN), Mirati Therapeutics (MRTX) to Collaborate on Diagnostic in Lung Cancer
Apr 13, 2016 04:05PM QIAGEN Partners to Develop Novel Companion Diagnostic in Lung Cancer
Dec 21, 2015 08:16AM Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)
Jul 7, 2015 11:32AM Biothera Pharmaceutical Inc. Announces Board of Directors
View More Recent Stories